GPP
MDGL icon

Great Point Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Great Point Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-95,500
Closed -$6.21M – 48
2022
Q3 		$6.21M Buy
+95,500
New +$6.64M 1.49% 23
2019
Q1 		– Sell
-27,500
Closed -$3.1M – 45
2018
Q4 		$3.1M Sell
27,500
-12,900
-32% -$2M 0.39% 34
2018
Q3 		$8.65M Buy
+40,400
New +$10.1M 1.35% 23

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Point Partners's MDGL Position: Q4 2022 in Review

Great Point Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2022, closing a stake of 95,500 shares — an estimated $6.21M sold.

Great Point Partners first reported a position in MDGL in Q3 2018 and held it in 3 quarters. The position peaked at $8.65M in Q3 2018. 188 funds tracked by Wall St. Rank hold MDGL as of Q4 2022.

  • Great Point Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Great Point Partners sold 95,500 Madrigal Pharmaceuticals shares in Q4 2022, an estimated $6.21M.
  • Great Point Partners first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Great Point Partners's Madrigal Pharmaceuticals position peaked at $8.65M in Q3 2018.
  • 188 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2022.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.